tbuckley/cabot-search huggingface dataset:
GENE-18. USE OF PRIMARY TEETH AND A TOOTH BRUSH AS SOURCES OF DNA IN AN ANAPLASTIC ASTROCYTOMA CASE
Authors: Sulgi Lee, Miriam Bornhorst, Cheng-Ying Ho, Joyce Turner, Eshini Panditharatna, Javad Nazarian
Journal: Neuro-Oncology (2017)

Anaplastic astrocytomas (AA) are aggressive glial cancers with poor prognosis and high recurrence. Although a majority of astrocytomas are sporadic, recent studies have shown that up to 10% of patients with cancer may have an underlying cancer predisposition syndrome. Identification of germline mutations allows for proper management and screening for cancer in patients and their at-risk family members. In this study, we present a unique case of two siblings who developed AA within 8 years of each other. Clinical whole exome testing of our patient’s germline DNA revealed a maternally inherited PTCH2 mutation of unknown significance. The PTCH2 gene is highly homologous to the PTCH1 gene, which is associated with increased risk for basal cell carcinoma, medulloblastoma, rhabdomyoma and ovarian fibroma. However, this has never been described in a glioma before. Prior to extracting DNA, the teeth were fragmented in liquid nitrogen and de-calcified in 1.0mM EDTA. The toothbrush was processed for DNA extraction by removing the head from the handle and submerging in Tris base solution. DNA extraction was performed using QIAamp DNA Mini-kit. Genomic DNA from the teeth and toothbrush were pre-amplified using primers for specific genes (H3F3A and IDH1) and detected by digital polymerase chain reaction (dPCR). PTCH2 gene germline mutation in DNA isolated from teeth and toothbrush were examined by Sanger sequencing. In this study, by using germline DNA from primary teeth and tooth brush of the brother, we were able to determine whether the PTCH2 germline mutation played a role in the development of astrocytomas in the two siblings. This method can be applied in many clinical scenarios where classification of germline variants is important for the determination of cancer risk in surviving family members.
Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2)
Authors: Jean Reignier, Julie Boisramé-Helms, Laurent Brisard, Jean-Baptiste Lascarrou, Ali Ait Hssain, Nadia Anguel, Laurent Argaud, Karim Asehnoune, Pierre Asfar, Frédéric Bellec, Vlad Botoc, Anne Bretagnol, Hoang-Nam Bui, Emmanuel Canet, Daniel Da Silva, Michael Darmon, Vincent Das, Jérôme Devaquet, Michel Djibre, Frédérique Ganster, Maité Garrouste-Orgeas, Stéphane Gaudry, Olivier Gontier, Claude Guérin, Bertrand Guidet, Christophe Guitton, Jean-Etienne Herbrecht, Jean-Claude Lacherade, Philippe Letocart, Frédéric Martino, Virginie Maxime, Emmanuelle Mercier, Jean-Paul Mira, Saad Nseir, Gael Piton, Jean-Pierre Quenot, Jack Richecoeur, Jean-Philippe Rigaud, René Robert, Nathalie Rolin, Carole Schwebel, Michel Sirodot, François Tinturier, Didier Thévenin, Bruno Giraudeau, Amélie Le Gouge, Hervé Dupont, Marc Pierrot, François Beloncle, Danièle Combaux, Romain Mercier, Hadrien Winiszewski, Gilles Capellier, Gilles Hilbert, Didier Gruson, Pierre Kalfon, Bertrand Souweine, Elizabeth Coupez, Jean-Damien Ricard, Jonathan Messika, François Bougerol, Pierre-Louis Declercq, Auguste Dargent, Audrey Large, Djillali Annane, Bernard Clair, Agnès Bonadona, Rebecca Hamidfar, Christian Richard, Mathieu Henry-Lagarrigue, Ahiem Yehia Yehia, Johanna Temime, Stephanie Barrailler, Raphaël Favory, Erika Parmentier-Decrucq, Mercé Jourdain, Loredana Baboi, Marie Simon, Thomas Baudry, Mehran Monchi, Jérôme Roustan, Patrick Bardou, Alice Cottereau, Philippe Guiot, Noelle Brule, Mickael Landais, Antoine Roquilly, Thierry Boulain, Dalila Benzekri, Benoit Champigneulle, Jalel Tahiri, Gabriel Preda, Benoit Misset, Virginie Lemiale, Lara Zafrani, Muriel Fartoukh, Guillaume Thiéry, Delphine Chatellier, Rémi Coudroy, Renaud Chouquer, Samuel Gay, Christine Brasse, Arnaud Delahaye, Gabriel Preda, Luis Ferreira, Régine Vermesch, Stéphanie Chevalier, Charlotte Quentin, Quentin Maestraggi, Francis Schneider, Ferhat Meziani, Charles Cerf, Grégoire Trebbia, Charlotte Salmon-Gandonnière, Laetitia Bodet-Contentin
Journal: The Lancet (2017)
ACTR-83. BEVACIZUMAB FOR RADIATION-INDUCED PSEUDOPROGRESSION IN ADULT SUPRASELLAR PILOCYTIC ASTROCYTOMA
Authors: Richard Green, Emily Woyshner, Timothy F Cloughesy
Journal: Neuro-Oncology (2017)

We report long term follow-up of 3 adult patients with unresectable suprasellar pilocytic astrocytoma who developed symptomatic worsening of neuroimaging soon after intensity-modulated radiation therapy (IMRT) and were treated with a combination of temozolomide and bevacizumab. The median age was 52 years (range, 24–52); 2 patients were men. After biopsy, patients were treated in the newly diagnosed setting with IMRT (dosage range 5220–6000 cGY). Soon after completion of RT (mean, 13 weeks) they exhibited increases in contrast enhancing volume and perilesional edema. Two patients had diplopia and one had visual loss. Two patients were treated with dexamethasone (mean, 8 mg daily) with inadequate control of symptoms. Treatment for suspected tumor progression was initiated with temozolomide 150–200 mg/sq m/d for 5/28 days (12 cycles) and bevacizumab 5 mg/kg (mean, 31 doses; range 25–43). All patients had rapid improvement of symptoms and MR imaging. No patient has yet experienced tumor progression, with a mean progression free interval of 409 weeks (298–474). In glioblastoma, pseudoprogression usually occurs within 6 months of completion of chemoradiation and can respond to bevacizumab. In retrospect, given the temporal proximity to the completion of IMRT and the durability of the responses, it appears likely that these patients actually had pseudoprogression rather than true progression. We suspect that they actually responded to the bevacizumab component of the regimen. Bevacizumab appears to be effective for treatment of pseudoprogression in adult suprasellar pilocytic astrocytoma.
Cannabinoids offer alternatives to opioids for pain relief, experts say
Authors: Bob Roehr
Journal: BMJ (2017)

Alternatives to opioids can be used alone or in combination with opioids for pain relief, to help prevent medical exposure to narcotics being an entry point to misuse, said experts at a medical education forum in Washington, DC on 3 November.

Endocannabinoid compounds found in marijuana can greatly enhance the potency of opioids in relieving pain. The synergy from using these drugs together can result in more effective pain relief from lower doses of opioids, explained Donald Abrams, an oncologist at the University of California, San Francisco, who conducted some of the US’s first clinical research on …
OA 03.04 A Phase II Study of Pembrolizumab for Patients with Refractory or Relapsed Thymic Epithelial Tumor
Authors: J. Cho, K.H. Yoo, H. Lee, H.K. Kim, Y. Kim, J.H. Cho, S.W. Lim, S.E. Park, J. Sun, S. Lee, J.S. Ahn, K. Park, M. Ahn
Journal: Journal of Thoracic Oncology (2017)
P3.02-013 Prognostic Role of Circulating Tumor DNA (ctDNA) and Immune Cell Biomarkers in Non-Small Cell Lung Cancer (NSCLC)
Authors: Y.K. Chae, S. Agte, A. Davis, A. Pan, N. Simon, N. Mohindra, V. Villaflor
Journal: Journal of Thoracic Oncology (2017)
Le système de surveillance épidémiologique mis en place dans le département des Hautes-Alpes pendant les Jeux Olympiques d’hiver, Turin 2006
Authors: F Franke, L Coulon, C Renaudat, B Euillot, N Kessalis, P Malfait
Journal: Eurosurveillance (2006)

Certaines competitions sportives des Jeux Olympiques d’hiver de Turin en Italie, organisees de fevrier a mars 2006, se sont deroulees a proximite de Briancon, dans les Hautes-Alpes.
Un systeme de veille sanitaire a ete mis en place par les autorites sanitaires locales, afin de detecter rapidement tout phenomene pouvant justifier une action de prevention ou de controle sanitaire et guider les interventions en cas d’epidemie ou pollution environnementale.
Une surveillance a ete assuree du 30 janvier au 15 mars 2006 sur l’arrondissement de Briancon.
Les nombres et les causes de deces etaient analyses. 
Un reseau de medecins generalistes surveillait les gastroenterites, la grippe et la rougeole. Les laboratoires de Briancon ont fourni les resultats des analyses realisees. Les activites des urgences du Centre hospitalier de Briancon et du Samu des Hautes-Alpes ont ete suivies. Les systemes des maladies a declaration obligatoire et des intoxications au monoxyde de carbone (CO) ont ete renforces. 
Les donnees analysees etaient transmises quotidiennement aux autorites sanitaires. Une retroinformation bilingue (francais/anglais) etait adressee chaque semaine aux differents partenaires.
Le taux de participation des partenaires a approche les 100% et les delais de transmission des informations respectes. Aucun evenement de sante n’a ete identifie dans la zone surveillee.
Le systeme de surveillance, structure autour du dispositif perenne de surveillance non specifique mis en place avec les hopitaux, Samu et etats civils, complete par des systemes ponctuels, a ete bien accepte et a permis de constituer la base d’une collaboration indispensable en cas d’epidemie ou de pollution environnementale.
Long-lasting strategy of pain management: the “comitato ospedale senza dolore”
Authors: K.F. Borgonovo, M. Cabiddu, F. Petrelli, M. Ghilardi, A. De Giuseppe, L. Brizzi, S. Silva, M. Destro, G. Dognini, L. Invernizzi, A. Ghedi, S. Barni
Journal: Annals of Oncology (2017)
DDIS-03. HARNESSING siRNA NANOMEDICINE FOR THERAPEUTIC GENE SILENCING IN GLIOBLASTOMA
Authors: Anna Gutkin, Dan Peer, Zvi Cohen
Journal: Neuro-Oncology (2017)

GBM is the most common primary brain tumor in adults, with a very poor prognosis. Despite tremendous efforts to develop new drugs, the treatment of GBM remains a great challenge. The use of nanoparticles (NPs) has emerged as a potential strategy for diagnosis and treatment of tumors, GBM especially. The key advantage of utilizing NPs as delivery platform is the ability to tailor-made them to achieve both controlled drug release and tissue specificity. We validated this strategy by direct injection of NPs to the tumor site and by systemic administration. Novel hyaluronan (HA)-grafted lipid nanoparticles (LNPs), devised in our laboratory, can carry siRNAs and bind to a specific CD44 variants expressed on tumor cells. We examined the effect of LNPs treatment on human GBM cell lines and cultured samples of GBM patients. HA-LNPs loaded with siRNA against the gene PLK1 (siPLK1) can induce eﬀective cell death in vitro. We also have shown that by direct injection of HA-siPLK1- LNPs to the brains of tumor bearing mice did not only decreased the levels of expression of the gene but also prolonged the survival of the mice by 60%, the longest ever reported survival of mice in this orthotopic GBM model in nude mice. Next, we have established a new model in our lab by injecting mouse glioma stem cells (GSCs) into a normal C57Bl/6 mice that resembles the characteristics of a human tumor. Using an in vivo fluorescent imaging system and confocal microscopy, we have shown that by systemic injection, HA-LNPs can reach the brain and enter the GSCs specifically. Our results suggest that treatment with our nanoparticles based system can specifically and efficiently target GBM cells in-vitro and in-vivo. This HA-LNPs based platform could potentially mature to a clinical trial, and ultimately might become a new therapeutic modality in GBM.
Epidemiología descriptiva de los exantemas en la región de Rotterdam, enero de 1997 a junio de 1998
Authors: F Termorshuizen, M J W van de Laar
Journal: Eurosurveillance (1998)

El Grupo Europeo de Asesoramiento en materia de Inmunizacion ha propuesto una serie de recomendaciones de cara a la eliminacion del sarampion en Europa para el ano 2007 (1), objetivo aprobado por los directores de los programas de inmunizacion de los paises pertenecientes a la region europea de la Organizacion Mundial de la Salud (OMS). En este contexto, el estudio de la epidemiologia de los exantemas (erupciones cutaneas asociadas a enfermedades febriles) es importante. El sarampion, considerado la forma mas frecuente de exantema en la infancia en Europa, es cada vez mas raro como consecuencia del aumento de la cobertura vacunal.
MA 13.09 Toxicity and Second Primary Lung Cancers in Late Survivors Following Lung SBRT
Authors: M. Giuliani, A. Hope, M. Guckenberger, F. Mantel, J. Sonke, H. Peulen, J. Belderbos, M. Werner-Wasik, H. Ye, I. Grills
Journal: Journal of Thoracic Oncology (2017)
P1.02-056 BRAF Non-V600E Mutations Recurrently Found in Non-Small Cell Lung Cancer in Chinese Patients
Authors: Q. Xu, W. Wang, C. Xu, W. Zhuang, Z. Song, Y. Zhu, Z. Xu, R. Chen, Y. Guan, X. Yi, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2017)
P2.01-021 Efficacy of Single-Agent Chemotherapy after Exposure to Nivolumab in Advanced Non-Small Cell Lung Cancer
Authors: Y. Yasuda, T. Funazo, T. Nomizo, T. Tsuji, H. Yoshida, Y. Sakamori, H. Nagai, H. Ozasa, T. Hirai, Y. Kim
Journal: Journal of Thoracic Oncology (2017)
New drug delivery system using an erythropoietin gelatin hydrogel sheet selectively protects the heart against myocardial infarction through activation of Akt and angiogenesis
Authors: Hiroyuki Kobayashi, Shinya Minatoguchi, Bao Narentuoya, Shinji Yasuda, Yu Misao, Hiroaki Ushikoshi, Masazumi Arai, Yoshihiro Uno, Genzo Takemura, Takako Fujiwara, Yasuhiko Tabata, Hisayoshi Fujiwara
Journal: Circulation (2006)
Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3
Authors: Zahid M. Delwar, Yvonne Kuo, Yan H. Wen, Paul S. Rennie, William Jia
Journal: Cancer Research (2017)

The first oncolytic virotherapy employing HSV-1 (oHSV-1) was approved recently by the FDA to treat cancer, but further improvements in efficacy are needed to eradicate challenging refractory tumors, such as glioblastomas (GBM). Microglia/macrophages comprising approximately 40% of a GBM tumor may limit virotherapeutic efficacy. Here, we show these cells suppress oHSV-1 growth in gliomas by internalizing the virus through phagocytosis. Internalized virus remained capable of expressing reporter genes while viral replication was blocked. Macrophage/microglia formed a nonpermissive OV barrier, preventing dissemination of oHSV-1 in the glioma mass. The deficiency in viral replication in microglial cells was associated with silencing of particular viral genes. Phosphorylation of STAT1/3 was determined to be responsible for suppressing oHSV-1 replication in macrophages/microglia. Treatment with the oxindole/imidazole derivative C16 rescued oHSV-1 replication in microglia/macrophages by inhibiting STAT1/3 activity. In the U87 xenograft model of GBM, C16 treatment overcame the microglia/macrophage barrier, thereby facilitating tumor regression without causing a spread of the virus to normal organs. Collectively, our results suggest a strategy to relieve a STAT1/3-dependent therapeutic barrier and enhance oHSV-1 oncolytic activity in GBM.Significance: These findings suggest a strategy to enhance the therapeutic efficacy of oncolytic virotherapy in glioblastoma. Cancer Res; 78(3); 718-30. ©2017 AACR.
P3.01-074 Genomic Analysis of Tumor and Plasma in T790M Mutant Positive EGFR Lung Cancer Patients before and after Osimertinib Treatment
Authors: J.C. Yang, C. Yu, J. Shih, C. Ho, W. Liao, J. Lee, T. Tsai, K. Su, M. Shih, Y.L. Chang, Y. Bai, D. Huang, K. Thress, C. Lin
Journal: Journal of Thoracic Oncology (2017)
P3.01-045 Correlation of EGFR Mutation Detection in CtDNA by Two Different Platforms in Advanced NSCLC Patients from a Single Institution
Authors: N. Vilariño, J.A. Puig-Butille, R. Reyes, I. Victoria, A. Arcocha, P. Jares, N. Viñolas, J.M. González De Aledo, R. Molina, C. Teixido, A. Prat, N. Reguart
Journal: Journal of Thoracic Oncology (2017)
2017 AHA Late-Breaking Basic Science Abstracts
Authors: Joon Park, Caroline Lee, Sungjin Yoon, Jong Kim, Sunghoon Kim, Bongyong Lee, Chen Gao, Yun-Hua Hsiao, Shuxun Ren, Grace Xiao, Yi Xing, Yibin Wang, Patrick Ernst, Ningning Xu, Kahyong Goh, Brian O'rourke, Jianyi Zhang, Margaret Liu, Lufang Zhou, Jessica Pfleger, Walter Koch, Stephen Chelko, Gizem Keceli, Peter Andersen, Nuria Amat-Codina, Jacopo Agrimi, Djahida Bedja, Marcus Stahlberg, Marc Halushka, Cynthia James, Hugh Calkins, Daniel Judge, Nazareno Paolocci, None Hansen, None Ssekayombya, Eric Green, Reinier Van Mourik, Charles Wolfus, Stephen Heitner, Onur Dur, Marc Semigran, South Myokardia, James Pilla, Terence Gade, Gabor Mizsei, Norman Butler, Yoshiaki Saito, Akito Imai, Keitaro Okamoto, Christopher Gade, Gabrielle Pilla, Jerry Zsido, Joseph Gorman, Robert Gorman
Journal: Circulation Research (2017)

Introduction: Prolyl-tRNA synthetase (PRS), a member of aminoacyl tRNA synthetases (ARS), is an enzyme that conjugates amino acid proline to its cognate tRNA to generate prolyl-tRNA to be used in protein synthesis.Since ARS are essential for protein synthesis and viability, dysregulation of ARS has been proposed to many human diseases.Cardiac fibrosis is characterized by excess production and deposition of ECM proteins by activated fibroblast.Although proline is a main component of collagen and ECM proteins, the exact mechanism and involvement of PRS in cardiac fibrosis has not yet been elucidated.Hypothesis: We hypothesized that suppression of PRS would down-regulate collagen synthesis, which could be beneficial in cardiac fibrosis.Results: To validate our hypothesis, we investigated the expression levels of pro-fibrotic markers by overexpression or knockdown of PRS in vitro.We showed that PRS is closely related to the expression of collagen I and α-SMA.Then, we showed that treatment of DWN12088, a novel small molecular selective inhibitor of PRS, reduced expression levels of pro-fibrotic markers in TGFβ-induced fibrotic environments using various cell-lines and primary fibroblasts.Interestingly, we showed that down-regulation of pro-fibrotic markers by DWN12088 is independent of TGFβ signaling pathway, although TGFβ is required for induction of pro-fibrotic markers.In vivo study, we performed transverse aortic constriction in C57BL/6 mice to evaluate the effect of DWN12088 in cardiac fibrosis.TAC results in pressure overload-induced left ventricular hypertrophy and fibrosis, and it is one of the most widely used models to study cardiovascular diseases.2-week oral treatment of DWN12088 markedly reduced cardiac fibrosis with ED 50 of 0.4 mg/kg, based on histological examinations.In addition, we demonstrated that 2-week oral treatment of DWN12088 showed reduction in infiltration of inflammatory cells, left ventricle thickness and accumulation of collagen fiber.Conclusion: These results suggest that inhibition of PRS attenuates pressure-overloaded cardiac fibrosis and a selective inhibitor of PRS, DWN12088, could serve as a potent anti-fibrotic agent without affecting critical cellular signaling cascade.
P3: Phylogenetic Posterior Prediction in RevBayes
Authors: Sebastian Höhna, Lyndon M Coghill, Genevieve G Mount, Robert C Thomson, Jeremy M Brown
Journal: Molecular Biology and Evolution (2017)

Tests of absolute model fit are crucial in model-based inference because poorly structured models can lead to biased parameter estimates. In Bayesian inference, posterior predictive simulations can be used to test absolute model fit. However, such tests have not been commonly practiced in phylogenetic inference due to a lack of convenient and flexible software. Here, we describe our newly implemented tests of model fit using posterior predictive testing, based on both data- and inference-based test statistics, in the phylogenetics software RevBayes. This new implementation makes a large spectrum of models available for use through a user-friendly and flexible interface.
P1.03-047 Carboplatin/ Weekly Nab-PTX in Elderly Patients with Previously Untreated Advanced Squamous NSCLC Selected Based on MNA-SF
Authors: S. Takata, T. Shiroyama, M. Tamiya, S. Minami, T. Uenami, H. Suzuki, N. Okamoto, K. Komuta, T. Hirashima, A. Kumanogoh, T. Kijima
Journal: Journal of Thoracic Oncology (2017)
ACTR-65. SAFETY PROFILE OF TUMOR TREATING FIELDS IN ADULT GLIOBLASTOMA PATIENTS WITH IMPLANTED NON-PROGRAMMABLE SHUNTS, PROGRAMMABLE SHUNTS, AND PACEMAKERS/DEFIBRILLATORS: 6-YEAR UPDATED RETROSPECTIVE ANALYSIS OF OPTUNE® THERAPY
Authors: Yvonne Kew, Alexis Demopoulos, Nancy Ann Oberheim-Bush, Jay-Jiguang Zhu
Journal: Neuro-Oncology (2017)

Tumor Treating Fields (TTFields) are a noninvasive, loco-regional, anti-mitotic cancer treatment approved in the U.S. for adults with recurrent and newly diagnosed glioblastoma (GBM). TTFields (low intensity, intermediate frequency, alternating electric fields) are delivered by a portable medical device (Optune®). GBM patients may develop hydrocephalus and benefit from subsequent shunt placement. Safety information on concomitant use of TTFields with implanted devices in GBM patients will identify potential interference with the functioning of these devices. A review of the clinical information for GBM patients treated with TTFields in the U.S. between November 2011 and June 2017 identified 50 patients with non-programmable shunts (NPS), 5 with programmable shunts (PS), and 5 with pacemakers/defibrillators (PM/DF). The safety data obtained from post-market surveillance in all 60 patients were analyzed to identify implantable device-related adverse events. Adverse events (AEs) reported for these 60 patients did not reveal any new safety concerns on concurrent use of Optune with implanted devices. Infections or infestations (bronchitis, diverticulitis, infection NOS, meningitis, sepsis, shunt infection, upper respiratory and urinary tract infections, wound infection) were reported in 7/50 (14%) of NPS patients and in 1/5 (20%) PS patient. No arrhythmia or other cardiac adverse events were reported in the 5 patients with PM/DF. Skin irritations were seen in 8% of NPS patients (including 2% ulcerations). Neurological symptoms (38%), which included convulsions (16%) in the NPS patients were related to the underlying tumor rather than TTFields treatment. Hydrocephalus was seen in 1/50 (2%) NPS and 1/5(20%) PS patient, neither related to shunt malfunction. No unexpected safety issues were observed in the 60 patients analyzed in this updated report. Further evaluation of the concurrent use of TTFields with programmable shunts and pacemaker/defibrillators should include bench testing of the electronic immunity of these devices to TTFields.
P3.13-033 DNA Methylation of PTGER4 and SHOX2 in Liquid Biopsies Facilitates the Diagnosis of Lung Malignancy After Chest CT-Scan
Authors: L. Schotten, K. Darwiche, C. Taube, C. Aigner, S. Welter, S. Eisenmann, A. Schlegel, T. Koenig, T. Hager, L. Freitag, K. He, F. Oezkan
Journal: Journal of Thoracic Oncology (2017)